



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	Ophthalmology Research: An international Journal
Manuscript Number:	2014_OR_11330
Title of the Manuscript:	Tachyphylaxis to ranibizumab in the treatment of age-related macular degeneration

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
MAJOR POINTS The first revision is not done accordingly. AMD and PCV are different diseases. The main treatment for PCV is photodynamic therapy. And you mention that the patients who had undergone photodynamic therapy were excluded. It is obvious that PCV patients will not be a well responder to anti-VEGF treatment. This is not understandable. The issue is so simple you cannot put AMD patients and PCV patients in the same group. The final message will be wrong. On the other hand if you want to use your PCV data, you can write another manuscript, regarding the results of anti-VEGF monotherapy for PCV. Also RAP patients should be evaluated separately, because it is obvious that they would not respond well to anti-VEGF treatment. MINOR POINTS There are still some typing mistakes.	I excluded PCV patients in my study, and revised some sentences.